

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

INSIDE INFORMATION – UPDATE ON BATOCLIMAB (HBM9161)

This announcement is made by HBM Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The Company has been made aware of a voluntary pause by Immunovant (Nasdaq: IMVT) in the clinical dosing of patients treated with IMVT-1401 in ASCEND GO-2, a phase 2b trial in Thyroid Eye Disease (TED), and in clinical studies in Warm Autoimmune Hemolytic Anemia (WAHA), due to the elevation of lipid testing results. Immunovant is a licensee of batoclimab for certain territories outside Greater China and is independently developing batoclimab in the United States. As of the date of this announcement, the Company has not observed similar findings in either its completed or on-going clinical studies with batoclimab. The Company already frequently monitors lipid levels in all its protocols across various indications and has no ongoing clinical trial with batoclimab in TED or WAHA.

The Company will continue to monitor the development of the evolving situation and may provide Immunovant with the required assistance in the course of its investigations.

This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman

Hong Kong, 2 February 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang, Dr. Mai-Jing Liao, and Dr. Atul Mukund Deshpande as executive Directors; Mr. Yu Min Qiu and Mr. Junfeng Wang as non- executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Ms. Weiwei Chen as independent non-executive Directors.